Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.70 |
| ▸ | NPC1 | O15118 | 7/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | PIM1 | P11309 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 3/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29848069 | 0.82 | MAPT (1.00) | RAB9ANPC1MAPTSMN1; SMN2ALOX15 | |
| SCHEMBL30100834 | 0.81 | NPC1 (0.71) | RAB9ANPC1MAPTSMN1; SMN2ALOX15 | |
| SCHEMBL13309209 | 0.81 | PIM1 (0.48) | RAB9ANPC1MAPTSMN1; SMN2ALOX15 | |
| SCHEMBL1602739 | 0.77 | RAB9A (0.69) | RAB9ANPC1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL30629233 | 0.77 | RAB9A (0.69) | RAB9ANPC1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL8707964 | 0.76 | PIM1 (0.68) | RAB9ANPC1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL3984529 | 0.75 | MAPT (0.57) | RAB9ANPC1MAPTSMN1; SMN2ALOX15 | |
| SCHEMBL29523120 | 0.74 | PIM1 (1.00) | RAB9ANPC1MAPTSMN1; SMN2PIM1 | |
| SCHEMBL2198563 | 0.74 | PIM1 (1.00) | RAB9ANPC1MAPTSMN1; SMN2PIM1 | |
| SCHEMBL2705460 | 0.74 | PIM1 (0.74) | RAB9ANPC1MAPTSMN1; SMN2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046350-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-02-23 | — | — | US | disclosed |
| EP-1558572-B1 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-06-30 | — | — | EP | disclosed |
| EP-1558571-B1 | NOVEL COMPOUNDS USEFUL IN TREATING PPAR MEDIATED DISEASES | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-06-02 | — | — | EP | disclosed |
| US-7709528-B2 | Compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-04 | — | — | US | disclosed |
| US-20060287393-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2006-12-21 | — | — | US | disclosed |
| EP-1558571-A1 | NOVEL COMPOUNDS USEFUL IN TREATING PPAR MEDIATED DISEASES | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | disclosed |
| EP-1558572-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | disclosed |
| US-20050080115-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2005-04-14 | — | — | US | disclosed |
| US-20050070583-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2005-03-31 | — | — | US | disclosed |
| WO-2004037775-A1 | NOVEL COMPOUNDS USEFUL IN TREATING PPAR MEDIATED DISEASES | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037776-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287393-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | RAB9A 2523/4885NPC1 500/4885MAPT 3498/4885 |
| US-20050070583-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | RAB9A 2523/4885NPC1 500/4885MAPT 3498/4885 |
| US-20050080115-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | RAB9A 2523/4885NPC1 500/4885MAPT 3498/4885 |
| US-20120046350-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | PPARG, PPARD, PPARA | RAB9A 2523/4885NPC1 500/4885MAPT 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.